Fisher & Paykel Healthcare (ASX:FPH) Ending Cash Position: A$378 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:FPH Fisher & Paykel Healthcare Corp Ltd ASX:FPH
88 GF Score
Price A$33.31
GF Value A$36.67
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare Ending Cash Position?

Fisher & Paykel Healthcare ASX:FPH +0.36% 88 Ending Cash Position is A$378 Mil as of Mar. 2026. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.67 (Fairly Valued). The stock has 2 warning signs investors should review.

Fisher & Paykel Healthcare's Ending Cash Position for the quarter that ended in Mar. 2026 was A$378 Mil.

Fisher & Paykel Healthcare's quarterly Ending Cash Position increased from Mar. 2025 (A$237 Mil) to Sep. 2025 (A$261 Mil) and increased from Sep. 2025 (A$261 Mil) to Mar. 2026 (A$378 Mil).

Fisher & Paykel Healthcare's annual Ending Cash Position increased from Mar. 2024 (A$75 Mil) to Mar. 2025 (A$237 Mil) and increased from Mar. 2025 (A$237 Mil) to Mar. 2026 (A$378 Mil).

Fisher & Paykel Healthcare Ending Cash Position Related Terms

Fisher & Paykel Healthcare Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Fisher & Paykel Healthcare's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fisher & Paykel Healthcare Ending Cash Position Chart

Fisher & Paykel Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.79 108.61 75.04 236.51 378.17

Fisher & Paykel Healthcare Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.04 106.98 236.51 261.38 378.17
ASX:FPH
88GF Score
Fisher & Paykel Healthcare Corp Ltd ASX:FPH
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fisher & Paykel Healthcare Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Fisher & Paykel Healthcare's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=216.833+161.334
=378

Fisher & Paykel Healthcare's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=244.251+133.916
=378

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$378 Mil mean?
Fisher & Paykel Healthcare (ASX:FPH) has a Ending Cash Position of A$378 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Fisher & Paykel Healthcare and its competitors.
Is Fisher & Paykel Healthcare's Ending Cash Position too high?
Fisher & Paykel Healthcare's current Ending Cash Position is A$378 Mil. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Ending Cash Position compare to ISRG and BDX?
Fisher & Paykel Healthcare's Ending Cash Position of A$378 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Fisher & Paykel Healthcare and its competitors. Fisher & Paykel Healthcare's current Ending Cash Position is A$378 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.67, compared to a current price of A$33.31 — trading 9.2% below its estimated fair value. The current Ending Cash Position is A$378 Mil. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Ending Cash Position is A$378 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of A$33.31 is trading 9.2% below its estimated GF Value™ of A$36.67. GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.

Key valuation signals for ASX:FPH:

  • Ending Cash Position: A$378 Mil
  • GF Value™: A$36.67 vs. price of A$33.31 (9.2% below fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fisher & Paykel Healthcare Business Description

Other Exchanges FSPKF:USAFPH:New Zealand
Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score

Get the complete analysis for ASX:FPH

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$33.31
Price
A$36.67
GF Value